[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100304716":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":62,"collaborators":19,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":19,"enrollmentInfo":75,"targetDuration":19,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HDR partial prostate brachytherapy","EXPERIMENTAL","2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI",[13],"Radiation: HDR partial prostate brachytherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","temporary radioactive implant",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Mira Keyes, MD","BCCA","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Juanita Crook, MD","CONTACT","2507123958","jcrook@bccancer.bc.ca",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"BCCA Center for the Southern Interior","RECRUITING","Kelowna","British Columbia","V1Y 5L3","Canada","CA",{"type":41,"coordinates":42},"Point",[43,44],-119.48568,49.88307,{"lat":44,"lon":43},[47,49,51,54,56,58,60],{"name":27,"role":28,"phone":48,"phoneExt":19,"email":30},"250 712 3958",{"name":27,"role":50,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"name":52,"role":53,"phone":19,"phoneExt":19,"email":19},"Deidre Batchelar, PhD","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":19,"phoneExt":19,"email":19},"Ross Halperin, MD",{"name":57,"role":53,"phone":19,"phoneExt":19,"email":19},"David Petrik, MD",{"name":59,"role":53,"phone":19,"phoneExt":19,"email":19},"David Kim, MD",{"name":61,"role":53,"phone":19,"phoneExt":19,"email":19},"Brenda Farnquist, MD",{"type":50,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Juanita Crook","Professor of Radiation Oncology","100304716","partial-prostate-salvage-high-dose-rate-brachytherapy-100304716",false,"NCT03246802","Partial Prostate Salvage High Dose Rate Brachytherapy","High Dose Rate Partial Prostate Brachytherapy as Salvage Treatment for Local Failures After Previous External Beam Radiotherapy","SalvageHDR","Inclusion Criteria:\n\n* Age \\>45 and Life expectancy \\>10 years\n* Previous External Beam Radiotherapy (EBRT) or LDR brachytherapy w\n* \\> 3 year interval since EBRT or LDR Brachytherapy\n* No late toxicity from prior EBRT ≥ grade 2\n* PSA \\> nadir + 2 ng\u002Fml and \\\u003C 10 ng\u002Fml\n* PSA Doubling time \\> 6 months\n* Radiographic evidence corresponding with site of recurrence in an under-dosed or untreated site. The recurrence should correspond to the site of original disease or be located in the seminal vesical +\u002F- adjacent prostate as only area of recurrence (i.e. unifocal recurrence).\n* Per Investigator, recurrence is suitable for implant with HDR brachytherapy and patient is suitable for procedure under anesthesia, spinal or general.\n* Negative staging of the abdomen\u002Fpelvis and bones.\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Not compliant with criteria above\n* Unable to give informed consent","MALE","45 Years",{"count":76,"type":77},30,"ESTIMATED","INTERVENTIONAL",[80],"NA","A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.",[83],"Recurrent Prostate Cancer",[85,86,87],"recurrent prostate cancer","mpMRI","salvage HDR brachytherapy","2026-06-24",{"date":90,"type":91},"2026-06-29","ACTUAL",{"date":93,"type":91},"2018-01-01",{"date":95,"type":77},"2037-01-01",{"name":5,"class":6},1]